Omicron Resists Pfizer Vaccine But Causes Less Severe Disease: Study

TUESDAY, Dec. 14, 2021 (HealthDay News) -- Compared to previous coronavirus variants, Omicron appears to cause less severe illness, but is more resistant to the Pfizer vaccine, researchers at South Africa's largest health insurer report.
The team at Discovery Health analyzed 211,000 positive coronavirus cases during the country's fourth wave, including 78,000 attributed to Omicron. It's the first major private study since the variant was first detected last month, the Washington Post reported.
The researchers found that during the latest wave, the risk of hospital admission among adults with COVID-19 was 29% lower than in the first pandemic wave that began in March 2020.
However, the Pfizer vaccine provided just 33% protection against infection with Omicron, a much lower rate than against other variants, according to the study.
The vaccine did give 70% protection against severe complications that would require hospitalization, which is "very good protection," the researchers said.
"This is the first time we've had any data on that," Dr. Eric Topol, vice president for research at Scripps Research in La Jolla, Calif., told USA Today.
"Seventy percent is definitely a dropdown. It isn't great. It was 95% effective [against] severe disease when it was Delta variant and then about 85% after six months of waning," Topol said.
Whether those numbers will continue to hold as more patients with Omicron are studied isn't yet clear, he added.
The South African researchers also found that children had a 20% higher risk of hospital admission with complications during the fourth wave than during the first wave, USA Today reported.
"What is encouraging at this stage is a flatter trajectory of hospital admissions indicating likely lower severity of this wave," Ryan Noach, Discovery's chief executive, said during a news briefing.
But earlier, he warned that South Africa's health care system could still be overwhelmed as Omicron continues to evolve.
"The Omicron-driven fourth wave has a significantly steeper trajectory of new infections relative to prior waves," Noach said in a statement. "National data show an exponential increase in both new infections and test positivity rates during the first three weeks of this wave, indicating a highly transmissible variant with rapid community spread of infection."
More information
Visit the U.S. Centers for Disease Control and Prevention for more on the Omicron variant.
SOURCES: Discovery Health, news release, Dec. 14, 2021; Washington Post; USA Today
- Pfizer Says Omicron-Specific Vaccine Ready by March - Consumer Health News | HealthDay ›
- Pfizer afirma que tendrá lista una vacuna específica para la ómicron en marzo - Consumer Health News | HealthDay ›
- Omicron Shows Signs of Ebbing as U.S. Cases Fall, Hospitalizations Level Off ›
- La ómicron muestra signos de menguar: los casos bajan y las hospitalizaciones se estabilizan en EE. UU. - Consumer Health News | HealthDay ›
- Scientists Watch, Worry About New 'Stealth' Version of Omicron Variant ›
- Los científicos vigilan una nueva versión 'sigilosa' de la variante ómicron que les preocupa - Consumer Health News | HealthDay ›
- ‘Stealth’ Version of Omicron Variant No Cause for Alarm, Experts Say - Consumer Health News | HealthDay ›
- La versión 'sigilosa' de la variante ómicron no es causa de alarma, afirman expertos - Consumer Health News | HealthDay ›
- ‘Deltacron’ Variant Rare and Not a Major Concern - Consumer Health News | HealthDay ›
- Two New Omicron Subvariants Fueling COVID Infections in New York State - Consumer Health News | HealthDay ›
- Dos nuevas subvariantes de la ómicron fomentan las infecciones con COVID en el estado de Nueva York - Consumer Health News | HealthDay ›